FINWIRES · TerminalLIVE
FINWIRES

ASX:RAC

6 stories mentioning ASX:RACUpdated just now

Every FINWIRES story that references ASX:RAC, newest first.

Asia

Racura Oncology Raises AU$34 Million to Fund Three Clinical Trials; Shares Up 3%

Racura Oncology (ASX:RAC) raised AU$34.3 million in total to fund three RC220 clinical trials in acute myeloid leukemia, epidermal growth factor receptor mutant lung cancer, and chemotherapy-related cardio-protection in solid tumor patients, according to a Tuesday filing with the Australian bourse.RC220 is the company's formulation of (E,E)-bisantrene, a small molecule anti-cancer agent, the filing said.The company has raised the funds since June 2024 through bonus and piggyback option conversions, private placements, and option underwriting, per the filing.Shares rose 3% in afternoon trade on Tuesday.

ASX:RAC
Asia

Racura Oncology Raises Over AU$24 Million Via Piggyback Option Offer; Shares Jump 6%

Racura Oncology (ASX:RAC) said it generated proceeds of about AU$24.4 million after a total of 19.5 million piggyback options were exercised out of the 20.1 million issued at its piggyback option offer, representing a 97% conversion rate, according to a Thursday Australian bourse filing.The proceeds provide additional capital to advance the company's clinical programs in acute myeloid leukemia, lung cancer, and anthracycline cardioprotection, as well as general working capital, per the filing.The company's shares rose nearly 6% in recent trading on Thursday.

ASX:RAC
Asia

Race Oncology Raises AU$1 Million in Strategic Placement

Race Oncology (ASX:RAC) secured around AU$1 million via a targeted private placement with a specialist healthcare-focused institutional investor, issuing 526,315 fully paid ordinary shares at AU$1.90 each, representing a 23% discount to its recent average market price, according to a Thursday filing with the Australian bourse.The company has raised a total of AU$31.2 million, including this placement and recent funds from piggyback and bonus option offers, to support the clinical development of RC220 and general working capital requirements, the filing added.

ASX:RAC
Asia

Racura Oncology Receives Clearance to Advance Dose Level in Phase One Cardioprotection, Anticancer Synergy Trial

Racura Oncology (ASX:RAC) received clearance from the Safety Review Committee to advance the RC220 dose in the first-phase Cardioprotection and Anticancer Synergy trial to the next designated dose level of 80 milligrams per square meter, according to a Friday filing with the Australian bourse.RC220 is the company's formulation of the anticancer agent (E,E)-bisantrene.The approval comes following confirmation that the drug showed an acceptable safety profile, with no dose-limiting toxicities or safety concerns noted during the observation period for the first three group one patients dosed at 40 milligrams per square meter, the filing said.

ASX:RAC
Asia

Racura Oncology Says Funding Sufficient for Activities Through 2027

Racura Oncology (ASX:RAC) said it ended the fiscal third quarter with a cash balance of about AU$19.4 million and is in a strong position to finance activities through 2027, according to a Thursday filing with the Australian bourse.The early conversion of options gave the company an additional AU$1.4 million of funding, per the filing.Racura Oncology said more than 81% of spending during the March quarter, or about AU$2.4 million, went toward research and development and drug manufacturing activities.

ASX:RAC
Asia

Racura Oncology, University of Wollongong Win New South Wales Government Funding for Cancer Study

Racura Oncology (ASX:RAC) and the University of Wollongong secured funding under the New South Wales government's TechVouchers program to study the efficacy of (E,E)-bisantrene for certain types of breast and ovarian cancers, according to a Wednesday filing with the Australian bourse.A collaboration between Racura and the University aims to produce preclinical evidence for the development of RC220 as a new targeted therapy, per the filing.Results from the collaboration are expected to come out over the next 12 months.Racura Oncology shares gained 2% in recent Wednesday trade.

ASX:RAC

Track with the FINWIRES app suite

FolioX
Track ASX:RAC in your portfolio
WheelAI
Analyze ASX:RAC options with the wheel strategy
StockInsider
See market sentiment on ASX:RAC
ASX:RAC News | FINWIRES